Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Want to see HK:2197 full AI Analyst Report?
Top Page
Clover Biopharmaceuticals Ltd.
(2197)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$3.00
▲(26.58% Upside)
Action:ReiteratedDate:04/28/26
The score is held down primarily by very weak financial performance (revenue collapse, persistent losses, negative equity, and continued cash burn). Technical indicators are a notable offset with price above major moving averages and positive MACD, but valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Proprietary technology platform
Owning a proprietary trimer-tag platform is a durable R&D asset that differentiates the company in vaccine design. It supports repeated product generation, potential licensing or partnerships, and raises the long-term odds of successful candidates versus firms without platform technology.
Negative Factors
Severe revenue collapse
A ~93% revenue drop in 2025 represents a structural loss of commercial scale and revenue predictability. Such a collapse undermines pricing power, reduces reinvestment capacity for R&D and manufacturing, and materially raises the likelihood of further downsizing or asset sales to survive.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary technology platform
Owning a proprietary trimer-tag platform is a durable R&D asset that differentiates the company in vaccine design. It supports repeated product generation, potential licensing or partnerships, and raises the long-term odds of successful candidates versus firms without platform technology.
Read all positive factors
Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.86B
Dividend YieldN/A
Average Volume (3M)29.82M
Price to Earnings (P/E)―
Beta (1Y)2.47
Revenue Growth-90.96%
EPS Growth77.66%
CountryHK
Employees300
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,298,038,500
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developi...
How the Company Makes Money
null...
Clover Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.41M | 38.42M | 39.26M | 0.00 | 0.00 |
| Gross Profit | -23.85M | -672.94M | 24.24M | -475.64M | -66.27M |
| EBITDA | -221.24M | -916.54M | -45.07M | -2.37B | -2.23B |
| Net Income | -199.78M | -903.43M | -138.54M | -2.45B | -6.02B |
Balance Sheet | |||||
| Total Assets | 458.12M | 812.74M | 2.10B | 4.69B | 5.35B |
| Cash, Cash Equivalents and Short-Term Investments | 286.15M | 427.53M | 766.26M | 1.64B | 2.87B |
| Total Debt | 10.62M | 89.64M | 334.45M | 354.37M | 67.92M |
| Total Liabilities | 2.26B | 2.45B | 2.83B | 5.36B | 4.13B |
| Stockholders Equity | -1.80B | -1.64B | -732.83M | -668.14M | 1.22B |
Cash Flow | |||||
| Free Cash Flow | -190.55M | -290.11M | -737.05M | -1.80B | -998.07M |
| Operating Cash Flow | -190.52M | -288.49M | -727.88M | -1.69B | -917.75M |
| Investing Cash Flow | -11.69K | 3.17M | -6.16M | -37.51M | 112.12M |
| Financing Cash Flow | -76.59M | -51.50M | -142.41M | 483.14M | 3.06B |
Clover Biopharmaceuticals Ltd. Technical Analysis
Positive
2.37
Price Trends
2.36
Positive
2.45
Positive
1.93
Positive
Market Momentum
0.21
Negative
63.56
Neutral
62.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Positive. The current price of 2.37 is below the 20-day moving average (MA) of 2.72, above the 50-day MA of 2.36, and above the 200-day MA of 1.93, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 63.56 is Neutral, neither overbought nor oversold. The STOCH value of 62.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2197.
Clover Biopharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.39B | 5.89 | 18.28% | ― | 314.06% | 3050.00% | |
49 Neutral | HK$3.86B | -13.26 | 11.40% | ― | -90.96% | 77.66% | |
48 Neutral | HK$1.33B | -4.06 | -102.50% | ― | 557.36% | -24.06% | |
44 Neutral | HK$2.41B | -3.21 | -137.11% | ― | ― | 2.11% | |
44 Neutral | HK$777.93M | -6.45 | 191.92% | ― | -100.00% | 77.06% | |
43 Neutral | HK$1.07B | -3.97 | -27.44% | ― | -33.80% | 31.29% |
* Healthcare Sector Average
HK:2197
Clover Biopharmaceuticals Ltd.
2.86
2.65
1261.90%
HK:9939
Kintor Pharmaceutical Ltd
2.87
1.67
139.17%
HK:2142
HBM Holdings Ltd.
13.47
4.87
56.63%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.07
-2.73
-35.00%
HK:2257
Sirnaomics Ltd.
6.63
3.60
118.81%
HK:6628
Transcenta Holding Limited
2.24
1.02
83.61%
Clover Biopharmaceuticals Ltd. Corporate Events
Clover Biopharmaceuticals Details Capped Payment Deal With Gavi, Easing US$224 Million Exposure
Apr 2, 2026
Clover Biopharmaceuticals has provided additional details on its settlement agreement with Gavi, the Vaccine Alliance, outlining a capped and structured schedule of semi-annual deferred payments and contingent success-based payments over a 12-year...
Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines
Mar 29, 2026
Clover Biopharmaceuticals has completed enrollment in an Australian Phase 2 clinical trial evaluating two respiratory combination vaccine candidates, SCB-1022 and SCB-1033, in 420 adults aged 60 to 85. The protein-based vaccines target RSV, hMPV a...
Clover Biopharmaceuticals Grants Over 19 Million Equity Awards to Align Pay With Performance
Mar 27, 2026
Clover Biopharmaceuticals has granted 10,195,500 share options and 8,965,000 restricted share units to 43 eligible participants under its post-IPO share option plan and RSU scheme as of March 27, 2026. The options, priced at HK$2.84 per share with...
Clover Narrows Loss as It Cuts Costs and Refocuses on Respiratory Vaccines
Mar 25, 2026
Clover Biopharmaceuticals reported a sharp contraction in revenue to RMB3.5 million in 2025, mainly from a return-rate adjustment on earlier AdimFlu-S (QIS) sales, while cash and bank balances fell by roughly half to RMB271.4 million amid loan rep...
Clover posts strong RSV re-vaccination data in head-to-head trial with GSK
Mar 25, 2026
Clover Biopharmaceuticals reported additional positive U.S. Phase I data for its RSV PreF vaccine candidate SCB-1019 in older adults previously vaccinated with GSK’s AREXVY. In a head-to-head re-vaccination study, SCB-1019 showed roughly 60-...
Clover Biopharmaceuticals Strikes Cap-Limited Settlement With Gavi to End Arbitration
Mar 22, 2026
Clover Biopharmaceuticals has reached a settlement with global vaccine alliance Gavi over a dispute concerning repayment of US$224 million in advance purchase funds. Under the agreement, wholly owned subsidiary Clover HK will make a US$7 million u...
Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend
Mar 13, 2026
Clover Biopharmaceuticals, Ltd. has scheduled a board meeting for March 25, 2026 to review and approve the annual results for the year ended December 31, 2025, and to consider the publication of those results. The board will also deliberate on whe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.